Combination therapy with cilostazol and pravastatin improves antiatherogenic effects in low ‐density lipoprotein receptor knockout mice

ConclusionsOur results suggest that combination therapy with pravastatin and cilostazol exerts beneficial effects by decreasing atherosclerotic lesion progression and improving the pro ‐inflammatory state in the vascular endothelium. These effects are mediated by the reduction in adhesion molecule expression, immune cell infiltration, and cytokine levels and the antiatherosclerotic modulation of serum cholesterol levels. Therefore, we conclude that combined treatment with pravas tatin and cilostazol may be a more effective antiatherosclerotic strategy than treatment with either agent alone.
Source: Cardiovascular Therapeutics - Category: Cardiology Authors: Tags: ORIGINAL RESEARCH ARTICLE Source Type: research